Skip to main content
Clinical Trials/NCT06255119
NCT06255119
Completed
N/A

The Feasibility of 3D Therapy Thrive for Inpatients With Opioid Use Disorder

3D Therapy, LLC1 site in 1 country40 target enrollmentOctober 18, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Opioid Use Disorder
Sponsor
3D Therapy, LLC
Enrollment
40
Locations
1
Primary Endpoint
Retention in Treatment
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their inpatient detox protocol.

Detailed Description

The primary objective of this study is to evaluate the feasibility and preliminary effectiveness of a novel virtual reality (VR) based intervention; 3D Therapy Thrive (3DTT). Inpatient detoxification can improve outcomes for individuals with opioid use disorder (OUD), however patients often leave treatment early due to mood, tension, and cravings associated with opioid withdrawal. Subjects were recruited from a community inpatient detoxification program and received up to two sessions of 3DTT. The patients completed surveys to assess their mood, distress, cravings, and overall satisfaction with the experience. Retention was measured by protocol completion as reported by clinic staff, independent of the study. A group of patients with OUD consecutively admitted to the program comprised a comparison treatment-as-usual (TAU) group.

Registry
clinicaltrials.gov
Start Date
October 18, 2022
End Date
December 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Retention in Treatment

Time Frame: At departure from facility, through study completion, an average of 10 days

Medical record indicating whether patient completed detox protocol (i.e., completed, left against medical advice, administratively discharged, or moved to higher level of care)

Feasibility and Tolerability of 3DTT

Time Frame: Immediately after each treatment

Feasibility and tolerability of 3DTT was measured by the Side Effects Questionnaire.

Secondary Outcomes

  • Mood(Before and after each treatment, approximately every other day for up to 5 days)
  • Anxiety(Before and after each treatment, approximately every other day for up to 5 days)
  • Cravings(Before and after each treatment, approximately every other day for up to 5 days)

Study Sites (1)

Loading locations...

Similar Trials